ash
ASH 2015 roundup: Amgen, MorphoSys, Novartis and Roche present new trial data
December 8, 2015Research and Development Amgen, Cancer, Novartis, Roche, ash, morphosys, oncology
Amgen Amgen presented data from three Phase II trials evaluating Blincyto (blinatumomab) in acute lymphoblastic leukemia (ALL)- a rare and …
Sandoz announces biosimilar successes
December 8, 2015Manufacturing and Production American Society of Hematology, Enbrel, Neulasta, Sandoz, ash, biosimilars, etanercept, pegfilgrastim
Novartis’ biosimilars division Sandoz has announced progress in its biosimilars programme, with its version of Amgen’s Neulasta proving as effective …
Takeda’s Ninlaro extends myeloma survival in trial
December 7, 2015Manufacturing and Production, Research and Development Ninlaro, Takeda, ash, ixazomib, multiple myeloma
Takeda has presented trial data showing that treatment with its oral proteasome inhibitor Ninlaro extended progression free survival by 35% …
Bayer and Novartis to debut new data at ASH 2015
November 30, 2015Research and Development, Sales and Marketing American Society of Hematology, Bayer, Conference, Novartis, ash, clinical trials, haematology, oncology
Pharma firms will present clinical trial results for the pipeline drugs they are pinning their 2016 hopes for success on, …
Takeda eyes new drug licences following positive blood cancer studies
December 11, 2014Research and Development, Sales and Marketing Adcetris, Takeda, Velcade, ash, bortezomib, brentuximab vedotin, hematology
Takeda is bringing its biotech arm in-house to create a global oncology business unit, which it says will drive forward …
Boehringer trials Pradaxa anti-bleeding antidote
December 11, 2014Sales and Marketing BMS, Bayer, Boehringer, Eliquis, Pradaxa, ash, dabigatran, idarucizumab
Boehringer Ingelheim says that its investigational drug can safely reverse the blood-thinning effect of its anti-clotting drug Pradaxa (dabigatran). The …
Latest content
